Man Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Man Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.33M	Sell	732,867 -560,433	-43%	-$5.07M	0.01%	941
2026 Q1	$12.3M	Buy	1,293,300 +885,450	+217%	+$6.88M	0.02%	717
2025 Q4	$3.18M	Buy	407,850 +53,366	+15%	+$386K	0.01%	1265
2025 Q3	$2.69M	Sell	354,484 -67,286	-16%	-$560K	﹤0.01%	1301
2025 Q2	$3.78M	Buy	421,770 +189,407	+82%	+$1.76M	0.01%	1174
2025 Q1	$1.74M	Buy	232,363 +142,409	+158%	+$1.15M	﹤0.01%	1410
2024 Q4	$676K	Buy	89,954 +28,481	+46%	+$216K	﹤0.01%	1588
2024 Q3	$467K	Buy	+61,473	New	+$467K	﹤0.01%	1673
2023 Q1	–	Hold	0	–	–	–	969
2020 Q1	–	Sell	-24,300	Closed	-$84K	–	1618
2019 Q4	$84K	Buy	+24,300	New	+$61.1K	﹤0.01%	1802

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Man Group's BCRX Position: Q2 2026 in Review

Man Group reduced its BioCryst Pharmaceuticals (BCRX) stake by 43% in Q2 2026, selling an estimated $5.07M and leaving 732,867 shares worth $7.33M. The position accounts for 0.01% of the portfolio, ranked #941.

Man Group first reported a position in BCRX in Q4 2019 and has held it in 9 quarters since. The position peaked at $12.3M in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Man Group held 732,867 shares of BioCryst Pharmaceuticals worth $7.33M as of Q2 2026.
Man Group sold 560,433 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $5.07M.
BioCryst Pharmaceuticals made up 0.01% of Man Group's portfolio in Q2 2026, its #941 holding.
Man Group first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 9 quarters since.
Man Group's BioCryst Pharmaceuticals position peaked at $12.3M in Q1 2026.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.